A test with an accuracy of 90% based on a simple blood test.
The study included 525 participants in good health aged 70 and older who provided blood samples at enrollment and at different times of the e, study.
During the five year follow-up, 74 participants developed Alzheimer’s disease or mild cognitive impairment of amnestic type with a significant loss of memory.
Of these, 46 were diagnosed during registration and 28 have developed these disorders during the study.
During the third year of the study, the researchers selected 53 people and 53 people in mental health to identify lipid biomarkers.
According to the researchers, these compounds are the result of the rupture of the membranes of neuronal cells in patients.
Blinded outcome confirmed that participants were adequately diagnosed based solely on the 10 identified lipids.
Result: ” The lipid profile was able to distinguish with 90% accuracy the two groups : participants who would progress to disease within two to three years, and those who remain healthy in the near future, ” says Professor.
Federoff, professor of neurology.
The researchers examined whether the presence of the APOE4 gene, a known risk factor for Alzheimer’s disease, could help improve their test, but it has not dreamed it be a significant predictor in this study.
An opportunity to develop new treatments?
This is the first study based on the use of blood biomarkers for diagnosing Alzheimer’s disease before symptoms.
But what may be the value of an early diagnosis so that there is no effective treatment against Alzheimer’s disease ? For Pr.
Federoff, interest is twofold.
On the one hand, “Our new blood test offers the possibility to identify individuals at risk of cognitive decline and may change the way patients, their families and their physicians manage disease, “said lead author.
On the other hand, Federoff believes that the reasons for the failures of drugs against Alzheimer’s disease may come too late for evaluation in the disease process.
” The preclinical state offers the opportunity to intervene at the right time to change the course of the disease,” says Federoff.
” Biomarkers like ours, capable of defining this asymptomatic period, are essential for the development and evaluation of these therapeutic “.
“We consider our results as an important step towards the commercialization of a test based on biomarkers of preclinical disease, a test that could be useful for screening scale to identify individuals at risk, “says Federoff.
” We are considering a clinical trial allowing us to use this test to identify people at high risk of Alzheimer’s disease to test a therapeutic agent that could delay or prevent the onset “.
Worldwide, approximately 35.6 million people suffer from Alzheimer’s disease and, according to the World Health Organization, the number will double every 20 years to reach 115.4 million patients by 2050.